MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)

QRxPharma Limited and (OTCQX: QRXPY) announced successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo™ IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery. When compared at equianalgesic doses with Percocet , the second most widely prescribed opioid in the US, MoxDuo™ IR demonstrated greater overall tolerability with substantially fewer incidences of moderate to severe nausea, vomiting, constipation, and hypotension than Percocet . Scheduled for launch in 2011, MoxDuo™ IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on...

Want to see the full article?

• Purchase this article for only $3.00